Study shows revisions in MPM staging system might be needed in future

The International Mesothelioma Interest Group (IMIG) staging system has been widely used, however, widespread concerns exist about the validity of the current malignant pleural mesothelioma (MPM) staging system. Concerns include that the system is derived from analysis of small, retrospective surgical series; it can be difficult to apply to clinical staging; and uses descriptors for lymph node involvement, which may not be relevant to MPM. Therefore, in collaboration with IMIG, the International Association for the Study of Lung Cancer (IASLC) has decided to update the staging system for MPM by developing a large international database.

A study, published in the November 2012 issue of the IASLC'S , reports the current by and large appropriately distinguishes among T and N categories and overall stages but also highlights areas for potential revision.

The study looked at 3,101 patients from 15 centers in four continents. The current data still represents mainly surgically treated patients. The authors report that current T descriptors are qualitative and most applicable to pathological staging. Possibly in the future, volumetric tumor measurement could enhance the current T descriptors.

In addition, the data demonstrate a difference in survival for node-negative versus node-positive patients. The difference between N1 and N2 disease is less clear, suggesting that additional study of the extent of lymph node involvement might yield improvements in the N-classification factor.

And finally the authors suggest that staging groups, especially for stages I and II disease, need to be reassessed. In the future, they say, "the addition of a larger group of patients with more advanced disease, staged clinically and managed nonsurgically may help determine whether stages III and IV should be classified into a and b subcategories."

add to favorites email to friend print save as pdf

Related Stories

New lung cancer staging system revealed

Jul 13, 2009

For the first time in more than 10 years, the universally accepted lung cancer staging system has been revised to more accurately reflect the prognosis for patients with non-small cell lung cancer (NSCLC).

The gold standard in cancer staging now as Web tool

Oct 05, 2010

Springer is launching the AJCC e-Staging Tool, a web-based application which will improve the way cancer is staged. Designed to meet the needs of the entire multidisciplinary team in any facility that deals with cancer, ...

Recommended for you

Discovery could lead to new cancer treatment

Aug 29, 2014

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

Aug 29, 2014

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments